The prevalence of oral lesions in HIV-infected homosex

Aids

5, 519-526

DOI: 10.1097/00002030-199105000-00007

Citation Report

#	Article	IF	CITATIONS
1	Progression and Clinical Outcome of Infection Due to Human Immunodeficiency Virus. Clinical Infectious Diseases, 1992, 14, 966-972.	5.8	36
2	Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis BMJ: British Medical Journal, 1992, 305, 921-925.	2.3	101
3	The Prevalence of Hairy Leukoplakia in HIV Seropositive and HIV Seronegative Immunocompromised Patients. International Journal of STD and AIDS, 1992, 3, 251-254.	1.1	4
4	Hairy leukoplakia in an HIV-negative, nonimmunosuppressed patient. Oral Surgery, Oral Medicine, and Oral Pathology, 1992, 74, 563-566.	0.6	41
5	Oral findings in Mexican AIDS patients with cancer. Journal of Oral Pathology and Medicine, 1993, 22, 87-91.	2.7	15
6	The prevalence of oral candidiasis in HIV-infected individuals and dental attenders in Edinburgh. Journal of Oral Pathology and Medicine, 1993, 22, 418-420.	2.7	21
7	Kaposi's sarcoma. Journal of the American Academy of Dermatology, 1993, 28, 371-395.	1.2	310
8	Toward Assessing Trends in Oral Mucosal Lesions: Lessons Learned From Oral Cancer. Advances in Dental Research, 1993, 7, 32-41.	3.6	13
9	The Role of Oral Candidiasis in Survival and Hospitalization Patterns: Analysis of an Inner City Hospital Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome Registry. American Journal of the Medical Sciences, 1993, 305, 345-353.	1,1	13
10	Azole resistance in oropharyngeal Candida albicans strains isolated from patients infected with human immunodeficiency virus. Antimicrobial Agents and Chemotherapy, 1994, 38, 2495-2497.	3.2	53
11	Resistant Candidiasis. AIDS Research and Human Retroviruses, 1994, 10, 925-929.	1.1	59
12	Correlation between antifungal susceptibility testing of Candida isolates from patients with HIV infection and clinical results after treatment with fluconazole. Infection, 1994, 22, 132-136.	4.7	49
13	Oral manifestations of HIV infection in homosexual men and intravenous drug users. Oral Surgery, Oral Medicine, and Oral Pathology, 1994, 78, 163-174.	0.6	80
14	Treatment of oral candidiasis in HIV infection. Oral Surgery, Oral Medicine, and Oral Pathology, 1994, 78, 211-215.	0.6	49
15	Oral manifestations associated with HIV-related disease as markers for immune suppression and AIDS. Oral Surgery, Oral Medicine, and Oral Pathology, 1994, 77, 344-349.	0.6	203
16	Dentists and AIDS: a Survey of Knowledge, Attitudes, and Behavior in Italy. Journal of Public Health Dentistry, 1994, 54, 145-152.	1.2	38
17	Building the Capacity for the Response of the Dental Profession to the Global HIV Pandemic: A Case Study in International Collaboration. Journal of Public Health Dentistry, 1994, 54, 234-237.	1.2	1
18	Invasive mycotic and actinomycotic oropharyngeal and craniofacial infection in two patients with AIDS. Mycoses, 1994, 37, 209-215.	4.0	17

#	Article	IF	CITATIONS
19	Epidemiology of oral candidiasis in HIV-infected patients: Colonization, infection, treatment, and emergence of fluconazole resistance. American Journal of Medicine, 1994, 97, 339-346.	1.5	329
20	Treatment of oropharyngeal candidiasis in HIV-positive patients. Journal of the American Academy of Dermatology, 1994, 31, S51-S55.	1.2	69
21	Stridor in patients with HIV infection. Journal of Laryngology and Otology, 1995, 109, 1197-1199.	0.8	11
22	Oral hairy leukoplakia in a HIV-negative asthmatic patient on systemic steroids. Journal of Oral Pathology and Medicine, 1995, 24, 282-284.	2.7	17
23	Transmission of Fluconazole-Resistant Candida albicans Between Patients with AIDS and Oropharyngeal Candidiasis Documented by Pulsed-Field Gel Electrophoresis. Clinical Infectious Diseases, 1995, 21, 561-564.	5.8	48
24	Opportunistic Candidiasis: An Epidemic of the 1980s. Clinical Infectious Diseases, 1995, 21, 897-904.	5.8	141
25	Exfoliative cytology and electron microscopy in the diagnosis of hairy leukoplakia. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 1995, 79, 564-569.	1.4	18
26	HIV-related oral disease. Lancet, The, 1996, 348, 729-733.	13.7	125
27	Oral hairy leukoplakia in 71 HIV-seropositive patients: Clinical symptoms, relation to immunologic status, and prognostic significance. Journal of the American Academy of Dermatology, 1996, 35, 928-934.	1,2	42
28	Asymptomatic oral yeast carriage in HIV-infected patients: frequency and fluconazole susceptibility profile. Clinical Microbiology and Infection, 1996, 1, 249-252.	6.0	10
29	Kaposi's Sarcoma An Update. Dermatologic Surgery, 1996, 22, 274-287.	0.8	6
30	Increasing access to dentists by HIV+ people: An intervention strategy. Journal of Continuing Education in the Health Professions, 1996, 16, 215-224.	1.3	0
31	Relationship of circulating CD4+ T-lymphocytes and p24 antigenemia to the risk of developing AIDS in HIV -infected subjects with oral hairy leukoplakia. Journal of Oral Pathology and Medicine, 1996, 25, 108-111.	2.7	23
32	Prognostic value of oral candidosis and hairy leukoplakia in 111 Mexican HIV-infected patients. Journal of Oral Pathology and Medicine, 1996, 25, 206-211.	2.7	23
33	Common Superficial Fungal Infections in Patients with AIDS. Clinical Infectious Diseases, 1996, 22, S128-S132.	5.8	100
34	Human Immunodeficiency Virusâ€"Related Oral Manifestations and Gender. Archives of Internal Medicine, 1996, 156, 2249.	3.8	44
35	The Accurate Diagnosis of Oral Lesions in Human Immunodeficiency Virus Infection: Impact on Medical Staging. JAMA Otolaryngology, 1996, 122, 68-73.	1,2	15
36	Analysis of the risk factors associated with the emergence of azole resistant oral candidosis in the course of HIV infection. Journal of Antimicrobial Chemotherapy, 1996, 38, 691-699.	3.0	55

#	Article	IF	Citations
37	Point Prevalence of Oropharyngeal Carriage of Fluconazoleâ€Resistant <i>Candida</i> In Human Immunodeficiency Virus–Infected Patients. Clinical Infectious Diseases, 1997, 25, 843-846.	5.8	54
38	Development of Oral Lesions in Human Immunodeficiency Virus-infected Transfusion Recipients and Hemophiliacs. American Journal of Epidemiology, 1997, 145, 164-174.	3.4	31
39	ORAL HEALTH PROBLEMS AND USE OF DENTAL SERVICES AMONG HIV-INFECTED ADULTS. Journal of the American Dental Association, 1997, 128, 1417-1422.	1.5	17
40	Oral manifestations in 70 German HIVâ€infected women. Oral Diseases, 1997, 3, S28-30.	3.0	27
41	Management of oral Kaposi's sarcoma and a proposal for clinical staging. Oral Diseases, 1997, 3, S124-8.	3.0	20
42	Oral ulceration in HIV infection: Investigation and pathogenesis. Oral Diseases, 1997, 3, S190-3.	3.0	39
43	Severe oral ulceration in patients with HIV infection: A case series. Oral Diseases, 1997, 3, S194-6.	3.0	17
44	Reductions in HIV-1 disease progression for zidovudine/lamivudine relative to control treatments. Aids, 1997, 11, 477-483.	2.2	56
45	Candidiasis. Aids, 1997, 11, 557-567.	2.2	205
46	Epidemiology of HIVâ€related oral manifestations in women: A review. Oral Diseases, 1997, 3, S18-27.	3.0	29
47	Sentinels and signposts: The epidemiology and significance of the oral manifestations of HIV disease. Oral Diseases, 1997, 3, S13-7.	3.0	70
48	Oral ulcers in HIVâ€infected patients: An update on epidemiology and diagnosis. Oral Diseases, 1997, 3, S183-9.	3.0	25
49	Oropharyngeal Candidiasis in Patients with AIDS: Randomized Comparison of Fluconazole Versus Nystatin Oral Suspensions. Clinical Infectious Diseases, 1997, 24, 1204-1207.	5.8	94
50	ORAL MANIFESTATIONS OF HUMAN IMMUNODEFICIENCY VIRUS INFECTION. Medical Clinics of North America, 1997, 81, 511-531.	2.5	5
51	Periodontal Status of HIVâ€1 and HIVâ€2 Seropositive and HIV Seronegative Female Commercial Sex Workers in Senegal. Journal of Periodontology, 1997, 68, 827-831.	3.4	34
52	HIVâ€associated oral lesions: Prevalence in Zambia. Oral Diseases, 1997, 3, S46-50.	3.0	36
53	Oral manifestations of HIV disease: An update. Seminars in Cutaneous Medicine and Surgery, 1997, 16, 257-264.	1.6	7
54	Quantitative cultures of <i>Candida</i> from mouthwash fluid in HIVâ€infected patients: a longitudinal study. Mycoses, 1997, 40, 377-380.	4.0	4

#	ARTICLE	IF	CITATIONS
55	Oral candidiasis in HIV infection: predictive value and comparison of findings in injecting drug users and homosexual men. Journal of Oral Pathology and Medicine, 1997, 26, 237-243.	2.7	31
56	Autopsy findings in the tongues of 20 patients with AIDS. Journal of Oral Pathology and Medicine, 1997, 26, 244-247.	2.7	6
57	Use of specialised isolation media for recognition and identification of Candida dubliniensis isolates from HIV-infected patients. European Journal of Clinical Microbiology and Infectious Diseases, 1997, 16, 296-300.	2.9	147
58	The effect of limited exposure to antimycotics on the relative cell-surface hydrophobicity and the adhesion of oral Candida albicans to buccal epithelial cells. Archives of Oral Biology, 1998, 43, 879-887.	1.8	47
59	Adhesion of oral Candida albicans isolates to denture acrylic following limited exposure to antifungal agents. Archives of Oral Biology, 1998, 43, 999-1007.	1.8	60
60	Oral health behaviour and the prevalence of oral manifestations of HIV infection in a group of HIV positive adults. International Dental Journal, 1998, 48, 557-562.	2.6	7
61	A Doubleâ€Blind Comparison of Itraconazole Oral Solution and Fluconazole Capsules for the Treatment of Oropharyngeal Candidiasis in Patients with AIDS. Clinical Infectious Diseases, 1998, 26, 1368-1373.	5.8	68
62	Oral Lesions among Women Living with or at Risk for HIV Infection. American Journal of Medicine, 1998, 104, 559-564.	1.5	48
63	Refractory Mucosal Candidiasis in Patients with Human Immunodeficiency Virus Infection. Clinical Infectious Diseases, 1998, 26, 556-565.	5.8	71
64	Oral examination: a screening tool for HIV infection?. Sexually Transmitted Infections, 1998, 74, 345-348.	1.9	19
65	Editorial Response: Antifungal Prophylaxis with Weekly Fluconazole for Patients with AIDS. Clinical Infectious Diseases, 1998, 27, 1376-1378.	5.8	8
66	Fluconazole susceptibility and strain variation of Candida albicans isolates from HIV-infected patients with oropharyngeal candidosis [published erratum appears in J Antimicrob Chemother 1998 Sep;42(3):413]. Journal of Antimicrobial Chemotherapy, 1998, 41, 541-548.	3.0	38
67	Fungus Among Us: Making a Mountain out of a "Mold―Hill. Journal of the American Geriatrics Society, 1998, 46, 916-917.	2.6	0
68	Do people with HIV/AIDS disclose their HIV-positivity to dentists?. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 1999, 11, 61-70.	1.2	33
69	Association of Plasma Levels of Human Immunodeficiency Virus Type 1 RNA and Oropharyngeal <i>Candida</i> Colonization. Journal of Infectious Diseases, 1999, 180, 534-537.	4.0	62
70	Candidemia in HIV-Infected Subjects. European Journal of Clinical Microbiology and Infectious Diseases, 1999, 18, 478-483.	2.9	37
71	Options for the Management of Mucosal Candidiasis in Patients with AIDS and HIV Infection. Pharmacotherapy, 1999, 19, 76-87.	2.6	53
72	ORAL INFECTIONS AND OTHER MANIFESTATIONS OF HIV DISEASE. Infectious Disease Clinics of North America, 1999, 13, 879-900.	5.1	42

#	Article	IF	CITATIONS
73	Effect of Receptive Oral Sex and Smoking on the Incidence of Hairy Leukoplakia in HIV-Positive Gay Men. Journal of Acquired Immune Deficiency Syndromes (1999), 1999, 21, 236.	2.1	45
74	Oral Mucosal Lesions and HIV Viral Load in the Women's Interagency HIV Study (WIHS). Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 25, 44-50.	2.1	81
75	Impact of protease inhibitor therapy on HIV-related oropharyngeal candidiasis. Aids, 2000, 14, 979-985.	2.2	78
76	Functions of oral candidiasis episodes that are highly prognostic for AIDS. , 2000, 19, 989-1004.		6
77	Cytokine profiles in parotid saliva from HIV-1-infected individuals: changes associated with opportunistic infections in the oral cavity. Oral Microbiology and Immunology, 2000, 15, 74-81.	2.8	22
78	Manifestações orais em pacientes com AIDS em uma população brasileira. Pesquisa Odontologica Brasileira = Brazilian Oral Research, 2000, 14, 79-85.	0.3	14
79	Thalidomide for the Treatment of Acquired Immunodeficiency Syndrome–Associated Refractory Oral Ulcers. JAMA Otolaryngology, 2000, 126, 89.	1.2	10
80	Oral Mucosal Lesions and HIV Viral Load in the Women's Interagency HIV Study (WIHS). Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 25, 44-50.	2.1	62
81	Sensitivity, specificity, and positive predictive value of oral opportunistic infections in adults with HIV/AIDS as markers of immune suppression and viral burden. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 2000, 90, 182-188.	1.4	109
82	Therapeutic Options for the Management of Oropharyngeal and Esophageal Candidiasis in HIV/AIDS Patients. HIV Clinical Trials, 2000, 1 , 47-59.	2.0	63
83	Oral Candidal Infections and Antimycotics. Critical Reviews in Oral Biology and Medicine, 2000, 11, 172-198.	4.4	191
84	Changing oral care needs in the United States: The continuing need for oral medicine. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 2001, 91, 34-44.	1.4	57
85	Prevalence of HIV-1 and oral lesions in pregnant women in rural Malawi. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 2001, 92, 56-61.	1.4	17
86	HIV-related oral manifestations among adolescents in a multicenter cohort study. Journal of Adolescent Health, 2001, 29, 109-114.	2.5	52
87	S2.3 Las candidosis orales en el paciente VIH (+): Ayer y Hoy. Gaceta Medica De Bilbao, 2001, 98, 102-103.	0.0	0
88	The urologist and the patient infected with human immunodeficiency virus or with acquired immunodeficiency syndrome. BJU International, 2001, 88, 500-510.	2.5	31
89	Adhesion of Candida parapsilosis to epithelial and acrylic surfaces correlates with cell surface hydrophobicity. Mycoses, 2001, 44, 29-35.	4.0	83
90	HIV protease inhibitors attenuate adherence of Candida albicansto epithelial cells in vitro. FEMS Immunology and Medical Microbiology, 2001, 31, 65-71.	2.7	62

#	Article	IF	CITATIONS
91	A Randomized, Doubleâ€Blind, Doubleâ€Dummy, Multicenter Trial of Voriconazole and Fluconazole in the Treatment of Esophageal Candidiasis in Immunocompromised Patients. Clinical Infectious Diseases, 2001, 33, 1447-1454.	5. 8	316
92	Evaluation of Differential Gene Expression in Fluconazole-Susceptible and -Resistant Isolates of Candida albicans by cDNA Microarray Analysis. Antimicrobial Agents and Chemotherapy, 2002, 46, 3412-3417.	3.2	93
93	Point prevalence, microbiology and fluconazole susceptibility patterns of yeast isolates colonizing the oral cavities of HIV-infected patients in the era of highly active antiretroviral therapy. Journal of Antimicrobial Chemotherapy, 2002, 50, 999-1002.	3.0	43
94	Effect of commercial ethanol propolis extract on the in vitro growth of Candida albicans collected from HIV-seropositive and HIV-seronegative Brazilian patients with oral candidiasis Journal of Oral Science, 2002, 44, 41-48.	1.7	24
95	Candida albicans adherence to resin-composite restorative dental material: Influence of whole human saliva. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 2002, 94, 589-592.	1.4	43
96	Oral candidiasis as a clinical marker related to viral load, CD4 lymphocyte count and CD4 lymphocyte percentage in HIV-infected patients. Journal of Oral Pathology and Medicine, 2002, 31, 5-10.	2.7	62
97	Co-existence between oral lesions and opportunistic systemic diseases among HIV-infected subjects in Thailand. Journal of Oral Pathology and Medicine, 2002, 31, 163-168.	2.7	25
98	The epidemiology of the oral lesions of HIV infection in the developed world. Oral Diseases, 2002, 8, 34-39.	3.0	76
99	Prevalence and classification of HIV-associated oral lesions. Oral Diseases, 2002, 8, 98-109.	3.0	101
100	Changes in the prevalence of HIV-associated mucosal disease at a dedicated clinic over $7\hat{a} \in f$ years. Oral Diseases, 2002, 8, 90-94.	3.0	39
101	Influence of antifungal polyenes on the adhesion of Candida albicans and Candida glabrata to human epithelial cells in vitro. Archives of Oral Biology, 2003, 48, 805-814.	1.8	25
102	HIV/AIDS orofacial lesions in 156 Zimbabwean patients at referral oral and maxillofacial surgical clinics. Oral Diseases, 2003, 9, 317-322.	3.0	59
103	Occurrence and Management of Opportunistic Infections Associated with HIV/AIDS in Asia. Journal of Health Management, 2003, 5, 237-260.	1.1	0
104	Genome-Wide Expression Profile Analysis Reveals Coordinately Regulated Genes Associated with Stepwise Acquisition of Azole Resistance in Candida albicans Clinical Isolates. Antimicrobial Agents and Chemotherapy, 2003, 47, 1220-1227.	3.2	151
105	Oral Opportunistic Infections in HIV-Positive Individuals: Review and Role of Mucosal Immunity. AIDS Patient Care and STDs, 2004, 18, 443-456.	2.5	45
106	Immunopathogenesis of Oropharyngeal Candidiasis in Human Immunodeficiency Virus Infection. Clinical Microbiology Reviews, 2004, 17, 729-759.	13.6	176
107	Effect of Epsteinâ€Barr Virus Replication on Langerhans Cells in Pathogenesis of Oral Hairy Leukoplakia. Journal of Infectious Diseases, 2004, 189, 1656-1663.	4.0	40
108	Proteomic Analysis of Azole Resistance in Candida albicans Clinical Isolates. Antimicrobial Agents and Chemotherapy, 2004, 48, 2733-2735.	3.2	60

#	Article	IF	CITATIONS
109	Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent. Alimentary Pharmacology and Therapeutics, 2004, 20, 475-481.	3.7	64
110	Self-care intervention to reduce oral candidiasis recurrences in HIV-seropositive persons: a pilot study. Community Dentistry and Oral Epidemiology, 2004, 32, 190-200.	1.9	11
111	Oro-facial lesions and CD4 counts associated with HIV/AIDS in an adult population in Oyo State, Nigeria. Oral Diseases, 2004, 10, 319-326.	3.0	45
112	Cutaneous markers of HIV infection. Clinics in Dermatology, 2004, 22, 487-498.	1.6	51
113	Risk indicators for oral candidiasis and oral hairy leukoplakia in HIV-infected adults. Community Dentistry and Oral Epidemiology, 2005, 33, 35-44.	1.9	63
114	DifferentialCandida albicanslipase gene expression during alimentary tract colonization and infection. FEMS Microbiology Letters, 2005, 244, 359-365.	1.8	50
115	A Randomized Study of the Use of Fluconazole in Continuous versus Episodic Therapy in Patients with Advanced HIV Infection and a History of Oropharyngeal Candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40. Clinical Infectious Diseases, 2005, 41, 1473-1480.	5.8	72
116	Application of Deoxyribonucleic Acid Microarray Analysis to the Study of Azole Antifungal Resistance in <i>Candida albicans</i> ., 2005, 118, 045-056.		1
117	Human Retroviral Infections in the Tropics. , 2005, , 852-883.		0
118	Colonization of Human Immunodeficiency Virus-Infected Outpatients in Taiwan with Candida Species. Journal of Clinical Microbiology, 2005, 43, 1600-1603.	3.9	50
119	Amlexanox for the Treatment of Recurrent Aphthous Ulcers. Clinical Drug Investigation, 2005, 25, 555-566.	2.2	81
120	Oral Lesions of HIV Disease and HAART in Industrialized Countries. Advances in Dental Research, 2006, 19, 57-62.	3.6	114
121	(A1) Identification of Oral Health Care Needs in Children and Adults, Management of Oral Diseases. Advances in Dental Research, 2006, 19, 106-117.	3.6	15
122	Molecular epidemiology of long-term colonization of Candida albicans strains from HIV-infected patients. Epidemiology and Infection, 2006, 134, 265-269.	2.1	22
123	Effect of prolonged HAART on oral colonization with Candidaand candidiasis. BMC Infectious Diseases, 2006, 6, 8.	2.9	42
124	Association of asymptomatic oral candidal carriage, oral candidiasis and CD4+ lymphocyte count in HIV-positive patients in China. Oral Diseases, 2006, 12, 41-44.	3.0	31
125	Genome-Wide Expression and Location Analyses of the <i>Candida albicans</i> Tac1p Regulon. Eukaryotic Cell, 2007, 6, 2122-2138.	3.4	118
126	Oral Candida colonization of human immunodeficiency virus infected subjects in Turkey and its relation with viral load and CD4+T-lymphocyte count. Mycoses, 2007, 50, 485-490.	4.0	35

#	Article	IF	CITATIONS
127	Oral manifestations of HIV infection by gender and transmission category in Mexico City. Journal of Oral Pathology and Medicine, 1998, 27, 135-140.	2.7	35
128	The effect of limited exposure to antifungal agents on the germ tube formation of oral Candida albicans. Journal of Oral Pathology and Medicine, 1998, 27, 213-219.	2.7	42
129	Adhesion of oral <i>C. albicans</i> to human buccal epithelial cells following limited exposure to antifungal agents. Journal of Oral Pathology and Medicine, 1998, 27, 325-332.	2.7	30
130	The <i>in vitro</i> postâ€antifungal effect of nystatin on Candida species of oral origin. Journal of Oral Pathology and Medicine, 1999, 28, 112-116.	2.7	42
131	HIV infection: oral lesions, CD4 ⁺ cell count and viral load in an Italian study population. Journal of Oral Pathology and Medicine, 1999, 28, 173-177.	2.7	87
132	Epidemiology, pathogenesis, and management of human immunodeficiency virus infection in patients with periodontal disease. Periodontology 2000, 2007, 44, 55-81.	13.4	33
133	EBV detection in HIV-related oral plasmablastic lymphoma. Oral Diseases, 2007, 13, 564-569.	3.0	23
134	Association of cutaneous and oral diseases in HIVâ€infected men. Oral Diseases, 1998, 4, 16-21.	3.0	21
135	Comparison of cytopathic changes in oral hairy leukoplakia with in situ hybridization for EBV DNA. Oral Diseases, 1998, 4, 95-99.	3.0	19
136	Oral manifestations of HIV in a southeast USA population. Oral Diseases, 1998, 4, 164-169.	3.0	66
137	The postantifungal effect (PAFE) of antimycotics on oral C. albicans isolates and its impact on candidal adhesion. Oral Diseases, 1998, 4, 260-267.	3.0	28
138	HIV TOPIC UPDATE: Prevalence and incidence of oral lesionsâ€"the changing scene. Oral Diseases, 2000, 6, 267-273.	3.0	23
139	Human immunodeficiency virusâ€positive individuals with oral hairy leukoplakia are able to mount cytotoxic T lymphocyte responses to Epsteinâ€Barr virus. Oral Diseases, 2000, 6, 40-47.	3.0	8
140	Prevalence of oral disease among adults with primary HIV infection*. Oral Diseases, 2008, 14, 497-499.	3.0	19
141	Species distribution and in vitro antifungal susceptibility of oral yeast isolates from Tanzanian HIV-infected patients with primary and recurrent oropharyngeal candidiasis. BMC Microbiology, 2008, 8, 135.	3.3	70
142	Aetiological factors for oral manifestations of HIV. Oral Diseases, 1996, 2, 193-197.	3.0	55
143	Antifungal activity of the plant Dodonaea viscosa var. angustifolia on Candida albicans from HIV-infected patients. Journal of Ethnopharmacology, 2008, 118, 173-176.	4.1	55
144	Oral Candidiasis as a Marker of HIV Disease Progression Among Zimbabwean Women. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 47, 579-584.	2.1	13

#	Article	IF	Citations
145	A Gain-of-Function Mutation in the Transcription Factor Upc2p Causes Upregulation of Ergosterol Biosynthesis Genes and Increased Fluconazole Resistance in a Clinical <i>Candida albicans</i> Isolate. Eukaryotic Cell, 2008, 7, 1180-1190.	3.4	203
146	Oral Complications of HIV Infection. , 2008, , 215-225.		2
147	Proteomic analysis of Mrr1p―and Tac1pâ€associated differential protein expression in azoleâ€resistant clinical isolates of <i>Candida albicans</i> . Proteomics - Clinical Applications, 2009, 3, 968-978.	1.6	11
148	The Oral HIV/AIDS Research Alliance: updated case definitions of oral disease endpoints. Journal of Oral Pathology and Medicine, 2009, 38, 481-488.	2.7	90
149	Oropharyngeal candidiasis and oral yeast colonization in Iranian Human Immunodeficiency Virus positive patients. Journal De Mycologie Medicale, 2010, 20, 8-14.	1.5	17
150	Mode of HIV transmission associated with risk of oral lesions in HIV-infected subjects in Thailand. Journal of Oral Pathology and Medicine, 2010, 39, 195-200.	2.7	15
151	Optimal management of oropharyngeal and esophageal candidiasis in patients living with HIV infection. HIV/AIDS - Research and Palliative Care, 2010, 2, 89.	0.8	40
152	Management of oropharyngeal and esophageal candidiasis in patients with HIV infection. HIV Therapy, 2010, 4, 325-343.	0.6	2
153	Candida albicans induces early apoptosis followed by secondary necrosis in oral epithelial cells. Molecular Oral Microbiology, 2010, 25, 215-225.	2.7	47
155	Diagnosis and Management of Oral Candidiasis. Otolaryngologic Clinics of North America, 2011, 44, 231-240.	1.1	38
156	Overview of the Oral HIV/AIDS Research Alliance Program. Advances in Dental Research, 2011, 23, 28-33.	3.6	16
157	Human Retroviral Infections in the Tropics. , 2011, , 541-558.		0
158	Mucocutaneous and Deeply Invasive Candidiasis., 2011,, 589-596.		1
159	Antifungal activity of lawsone methyl ether in comparison with chlorhexidine. Journal of Oral Pathology and Medicine, 2011, 40, 90-96.	2.7	35
160	Buccoadhesive Dosage Form Containing Antifungal Agent for Treating Oropharyngeal Candidiasis: A Review. Current Drug Therapy, 2011, 6, 55-64.	0.3	2
161	Aspartic Protease Inhibitors as Potential Anti-Candida albicans Drugs: Impacts on Fungal Biology, Virulence and Pathogenesis. Current Medicinal Chemistry, 2011, 18, 2401-2419.	2.4	54
162	Variation in Genes of \hat{l}^2 -glucan Recognition Pathway and Susceptibility to Opportunistic Infections in HIV-Positive Patients. Immunological Investigations, 2011, 40, 735-750.	2.0	7
163	Gain-of-Function Mutations in <i>UPC2</i> Are a Frequent Cause of <i>ERG11</i> Upregulation in Azole-Resistant Clinical Isolates of Candida albicans. Eukaryotic Cell, 2012, 11, 1289-1299.	3.4	207

#	Article	IF	Citations
164	Oral complications of HIV infection. , 2012, , 195-206.		2
165	Asymptomatic oral yeast carriage and antifungal susceptibility profile of HIV-infected patients in Kunming, Yunnan Province of China. BMC Infectious Diseases, 2013, 13, 46.	2.9	45
166	Effects of lawsone methyl ether mouthwash on oral <i><scp>C</scp>andida</i> in <scp>HIV</scp> â€infected subjects and subjects with denture stomatitis. Journal of Oral Pathology and Medicine, 2013, 42, 698-704.	2.7	24
167	Factors associated with specific clinical forms of oral candidiasis in HIV-infected Brazilian adults. Archives of Oral Biology, 2013, 58, 657-663.	1.8	14
168	Smoking Is an Independent Risk Factor for the Development of Oral Candidiasis (OC) in HIV-1 Infected Persons. Journal of Evidence-based Dental Practice, 2013, 13, 180-182.	1.5	3
169	Oropharyngeal <scp>C</scp> andida colonization in human immunodeficiency virus infected patients. Apmis, 2013, 121, 375-402.	2.0	17
170	A Comparative Study of Oral Candidal Carriage and Its Association with CD4 Count between HIV-Positive and Healthy Individuals. Journal of the International Association of Providers of AIDS Care, 2013, 12, 39-43.	1.5	7
171	Levels of HIVâ€1 in subgingival biofilm of HIVâ€infected patients. Journal of Clinical Periodontology, 2014, 41, 1061-1068.	4.9	5
172	Structural basis for heterogeneous phenotype of ERG11 dependent Azole resistance in C.albicans clinical isolates. SpringerPlus, 2014, 3, 660.	1.2	18
173	Immediate Loading With Fixed Implant-Supported Restorations in an Edentulous Patient With an HIV Infection. Implant Dentistry, 2014, 23, 8-12.	1.3	11
174	<i>UPC2</i> Is Universally Essential for Azole Antifungal Resistance in Candida albicans. Eukaryotic Cell, 2014, 13, 933-946.	3.4	58
175	Role of autophagy genetic variants for the risk of Candida infections. Medical Mycology, 2014, 52, 333-341.	0.7	17
176	Oral manifestations of systemic disease. InnovAiT, 2014, 7, 209-215.	0.0	1
177	Role of oral candidiasis in TB and HIV co-infection: AIDS Clinical Trial Group Protocol A5253. International Journal of Tuberculosis and Lung Disease, 2014, 18, 682-688.	1.2	11
178	General Clinical Manifestations of Human Immunodeficiency Virus Infection (Including Acute) Tj ETQq0 0 0 rgBT 1541-1557.e5.	/Overlock	10 Tf 50 187 5
179	Antifungal effect of Trachyspermum ammi against susceptible and fluconazole-resistant strains of Candida albican s. Journal De Mycologie Medicale, 2015, 25, 143-150.	1.5	22
180	Efficacy of nystatin for the treatment of oral candidiasis: a systematic review and meta-analysis. Drug Design, Development and Therapy, 2016, 10, 1161.	4.3	124
181	High Oral Carriage of Non- albicans Candida spp. among HIV-infected individuals. International Journal of Infectious Diseases, 2016, 49, 185-188.	3.3	47

#	Article	IF	CITATIONS
182	Hairy leukoplakia; lessons learned: 30â€plus years. Oral Diseases, 2016, 22, 120-127.	3.0	53
183	Autoimmunity and dysmetabolism of human acquired immunodeficiency syndrome. Immunologic Research, 2016, 64, 641-652.	2.9	7
184	The Aryl Hydrocarbon Receptor Governs Epithelial Cell Invasion during Oropharyngeal Candidiasis. MBio, 2017, 8, .	4.1	50
185	Oral candidiasis among African human immunodeficiency virus-infected individuals: 10 years of systematic review and meta-analysis from sub-Saharan Africa. Journal of Oral Microbiology, 2017, 9, 1317579.	2.7	37
186	Predictors of esophageal candidiasis among patients attending endoscopy unit in a tertiary hospital, Tanzania: a retrospective cross-sectional study. African Health Sciences, 2018, 18, 66.	0.7	22
187	Evaluation of dental students' knowledge and patient care towards HIV/AIDS individuals. European Journal of Dental Education, 2019, 23, 212-219.	2.0	9
188	T Cell Antifungal Immunity and the Role of C-Type Lectin Receptors. Trends in Immunology, 2020, 41, 61-76.	6.8	71
189	Evaluation of oral care protocols practice by dentists in Rio de Janeiro towards HIV/AIDS individuals. BMC Oral Health, 2020, 20, 13.	2.3	8
190	Health Behavior Research and Oral Health. , 1997, , 121-142.		2
191	Oral Manifestations of Viral Diseases. , 2006, , 99-156.		4
192	Kaposi's Sarcoma: A Reevaluation. Recent Results in Cancer Research, 1995, , 275-296.	1.8	23
193	Salivary Diagnostics and the Oral Microbiome. , 2015, , 83-119.		4
194	General Clinical Manifestations of Human Immunodeficiency Virus Infection (Including the Acute) Tj ETQq0 0 0 rg	gBT /Overl	ock 10 Tf 50 2 3
195	Dental Service Use Among Adults with Human Immunodeficiency Virus Infection. Medical Care, 1997, 35, 77-85.	2.4	35
196	Prophylaxis with Nystatin Pastilles for HIV-Associated Oral Candidiasis. Journal of Acquired Immune Deficiency Syndromes, 1996, 12, 470-476.	0.3	25
197	Effect of Cigarette Smoking on HIV-Related Oral Lesions. Journal of Acquired Immune Deficiency Syndromes, 1997, 14, 338-342.	0.3	53
198	Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection. Journal of Clinical Microbiology, 1994, 32, 2092-2098.	3.9	246
199	Cluster of oral atypical Candida albicans isolates in a group of human immunodeficiency virus-positive drug users. Journal of Clinical Microbiology, 1995, 33, 1129-1135.	3.9	103

#	Article	IF	CITATIONS
200	Typing Candida albicans oral isolates from human immunodeficiency virus-infected patients by multilocus enzyme electrophoresis and DNA fingerprinting. Journal of Clinical Microbiology, 1996, 34, 1235-1248.	3.9	71
201	Evaluation of the Fungitest Kit by Using Strains from Human Immunodeficiency Virus-Infected Patients: Study of Azole Drug Susceptibility. Journal of Clinical Microbiology, 1999, 37, 864-866.	3.9	16
202	High Accuracy of Common HIV-Related Oral Disease Diagnoses by Non-Oral Health Specialists in the AIDS Clinical Trial Group. PLoS ONE, 2015, 10, e0131001.	2.5	21
203	Superficial and Mucosal Fungal Infections. Infectious Disease and Therapy, 2007, , 153-170.	0.0	2
204	Anti Yeast Activity of Streptomyces olivaceus Strain 115 Against Candida albicans. Journal of Applied Sciences, 2006, 6, 524-526.	0.3	1
205	Gender differences in oral lesions among persons with HIV disease in Southern India. Journal of Oral and Maxillofacial Pathology, 2012, 16, 388.	0.6	13
206	Oral Cavity Manifestations., 2001,, 115-121.		0
207	The Role of Resistance in Candida Infections: Epidemiology and Treatment. , 2009, , 931-951.		1
208	HIV/AIDS and Oral Health in Socially Disadvantaged Communities. , 0, , .		0
209	Reconstitution of the immunological defence and <i> Candida albicans < li > infection in oral mucosa of HIV+ patients under HAART. JORDI - Journal of Oral Diagnosis, 2016, 1, .</i>	0.0	0
217	Toward improving the oral health of Americans: an overview of oral health status, resources, and care delivery. Oral Health Coordinating Committee, Public Health Service. Public Health Reports, 1993, 108, 657-72.	2.5	30
218	Molecular identification of Candida species isolated from gastro-oesophageal candidiasis in Tehran, Iran. Gastroenterology and Hepatology From Bed To Bench, 2015, 8, 288-93.	0.6	8
222	ORAL MANIFESTATIONS OF' HUMAN IMMUNODEFICIENCY VIRUS INFECTION. Dental Clinics of North America, 1993, 37, 21-32.	1.8	34
223	Orale manifestasjoner ved HIV-infeksjon. , 2006, 116, .		2
224	Deborah Greenspan: A pioneer in the field of oral <scp>HIV</scp> disease. Oral Diseases, 2023, 29, 886-889.	3.0	1
225	Current Oral Manifestations of HIV Infection. Journal of the California Dental Association, 2001, 29, 137-141.	0.1	1
226	Bilateral Vestibuloplasty Utilizing Palatal Soft Tissue Grafts in an HIV-Positive Patient. Journal of the California Dental Association, 2009, 37, 467-470.	0.1	3
227	Common Oral Manifestations of Select Systemic Diseases: Anemia, Diabetes Mellitus and HIV. Journal of the California Dental Association, 2016, 44, 553-559.	0.1	4

#	Article	IF	CITATIONS
228	An Appreciation of a Giant in Orofacial Sciences Researchâ€"John Greenspan. Journal of Dental Research, 0, , .	5.2	0